ArticleClinical & translational immunology2019
Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab.
Renee Berry et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it